Clinical trials for Pelvic inflammatory disease

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Pelvic inflammatory disease. For all clinical trials, go to clinical trials search

This list shows clinical trials for Pelvic inflammatory disease

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Pelvic inflammatory disease
Title Recruitment status Location
Azithromycin for the treatment of pelvic inflammatory disease (PID) Recruiting United Kingdom
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Recruiting United Kingdom
A Multicenter study on the efficacy and safety of Vivaglobin in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID) - ND Not Recruiting United Kingdom
A clinical trial with a subcutaneous immunoglobulin (LFB-IgSC) to evaluate its efficacy, its safety and its behaviour in human blood in patients with Primary Immunodeficiency (PID) syndromes Not Recruiting United Kingdom
CLINICAL STUDY OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS IMMUNE GLOBULIN, 20% IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES Not Recruiting United Kingdom
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID) Not Recruiting United Kingdom
The tolerability of Octagam® 5% and Octagam® 10% Not Recruiting United Kingdom
A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome - Oral Sorafenib in renal cancer patients with vHL syndrome Not Recruiting United Kingdom
CLINICAL STUDY OF THE EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS IMMUNE GLOBULIN, 20% IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES Not Recruiting United Kingdom
A Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency Not Recruiting United Kingdom

Page last reviewed:

Next review due: